Baclofen is the Best Medication for Alcohol Abstinence in Cirrhosis
For patients with cirrhosis and alcohol use disorder, baclofen (30-60 mg/day) is the recommended first-line pharmacotherapy, as it is the only medication specifically studied and proven effective in this population through randomized controlled trials. 1
Evidence-Based Rationale
The 2020 AASLD practice guidance explicitly identifies baclofen as the sole AUD medication tested in RCTs specifically for patients with cirrhosis 1. In the landmark trial, baclofen (10 mg three times daily for 12 weeks) achieved 71% abstinence versus 29% with placebo in alcohol-dependent patients with both compensated and decompensated cirrhosis (OR 6.3, p=0.0001), with cumulative abstinence duration twice as long (62.8 vs 30.8 days) 2. The drug demonstrated an acceptable safety profile with no hepatic side effects 2.
Critical Caveat: Hepatic Encephalopathy
Exclude patients with hepatic encephalopathy from baclofen treatment, as it may impair mentation—a side effect exacerbated in advanced liver disease 1. Monitor closely for worsening mental status and sedation, particularly given its GABA-B receptor agonist mechanism 1.
Alternative Options and Their Limitations
Naltrexone: Emerging Evidence but Historical Concerns
While the most recent 2026 NAL-CI trial showed impressive results in compensated cirrhosis (64% vs 22% abstinence, p<0.001) 3, and multiple 2026 publications advocate for its safety 4, 5, the AASLD guidelines explicitly note naltrexone has NOT been studied in patients with ALD and carries hepatotoxicity concerns due to hepatic metabolism 1. The guideline evidence takes precedence, though the emerging research suggests this may be overly cautious for compensated cirrhosis specifically.
Acamprosate: Safer Profile but Unstudied
Acamprosate has no hepatic metabolism and no reported hepatotoxicity 1. A 2022 real-world study suggested it may be safer than baclofen (fewer unplanned admissions: OR 0.284, p=0.025) 6. However, acamprosate has never been studied in patients with cirrhosis in controlled trials 1, and the AASLD guidance states it "does not appear to be toxic to the liver and is probably safe" based on limited data 1—a weaker recommendation than baclofen's proven efficacy.
Explicitly Contraindicated
Disulfiram is NOT recommended for use in patients with ALD due to hepatic metabolism and potential for liver damage 1.
Practical Implementation Algorithm
- Screen for hepatic encephalopathy (exclude if present)
- Assess liver disease severity (Child-Pugh score, MELD-Na)
- First-line: Baclofen 10 mg three times daily for 12 weeks minimum
- Monitor for: sedation, worsening mental status, renal dysfunction
- If baclofen contraindicated/not tolerated:
- Compensated cirrhosis only: Consider naltrexone 50 mg/day (off-label, emerging evidence)
- Any cirrhosis stage: Consider acamprosate 666 mg TID (renally excreted, adjust for renal function)
Integration with Psychosocial Treatment
Combine pharmacotherapy with integrated AUD treatment and medical care, as this remains the best-supported approach for advanced ALD 1. The medication alone is insufficient—psychosocial interventions (CBT, motivational interviewing, mutual aid societies) should be concurrent 1.
The strength of baclofen's recommendation stems from being the only medication with Level 1 evidence (RCT) specifically in the cirrhosis population, despite newer data suggesting naltrexone may be equally effective and safe in compensated disease. Until guidelines are updated to reflect the 2026 naltrexone trials, baclofen remains the evidence-based standard of care.